Scilex (SCLX) Competitors

Vaccitech (NASDAQ:VACC) and Scilex (NASDAQ:SCLX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends, profitability and community ranking.

Which has preferable earnings & valuation, VACC or SCLX?

Vaccitech has higher earnings, but lower revenue than Scilex. Vaccitech is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vaccitech	$13.42M	7.47	$5.34M	-$1.43	-1.82
Scilex	$46.74M	3.77	-$114.33M	-$1.29	-0.82

Do analysts recommend VACC or SCLX?

Vaccitech presently has a consensus target price of $7.63, suggesting a potential upside of 193.27%. Scilex has a consensus target price of $8.00, suggesting a potential upside of 665.55%. Given Vaccitech's stronger consensus rating and higher probable upside, analysts clearly believe Scilex is more favorable than Vaccitech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vaccitech	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.50
Scilex	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is VACC or SCLX more profitable?

Scilex has a net margin of -244.60% compared to Scilex's net margin of -409.18%. Vaccitech's return on equity of 0.00% beat Scilex's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vaccitech	-409.18%	-23.41%	-20.85%
Scilex	-244.60%	N/A	-112.17%

Does the MarketBeat Community believe in VACC or SCLX?

Vaccitech received 14 more outperform votes than Scilex when rated by MarketBeat users. However, 100.00% of users gave Scilex an outperform vote while only 70.83% of users gave Vaccitech an outperform vote.

Company	Underperform	Outperform
Vaccitech	Outperform Votes 17 70.83%	Underperform Votes 7 29.17%
Scilex	Outperform Votes 3 100.00%	Underperform Votes No Votes

Which has more risk & volatility, VACC or SCLX?

Vaccitech has a beta of -0.4, suggesting that its share price is 140% less volatile than the S&P 500. Comparatively, Scilex has a beta of 0.68, suggesting that its share price is 32% less volatile than the S&P 500.

Do insiders and institutionals hold more shares of VACC or SCLX?

26.1% of Vaccitech shares are owned by institutional investors. Comparatively, 69.7% of Scilex shares are owned by institutional investors. 6.0% of Vaccitech shares are owned by insiders. Comparatively, 8.7% of Scilex shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Does the media favor VACC or SCLX?

In the previous week, Scilex had 3 more articles in the media than Vaccitech. MarketBeat recorded 4 mentions for Scilex and 1 mentions for Vaccitech. Scilex's average media sentiment score of 0.59 beat Vaccitech's score of 0.00 indicating that Vaccitech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vaccitech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scilex	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Scilex beats Vaccitech on 13 of the 18 factors compared between the two stocks.